Bone marrow transplantation with interleukin-2-activated bone marrow
followed by interleukin-2 therapy for acute myeloid leukemia in mice
BS Charak, RK Brynes, S Groshen, SC Chen and A Mazumder
Department of Medicine, University of Southern California, Los Angeles.
We have investigated approaches to induce graft-versus-leukemia (GVL)
effect in autologous bone marrow transplantation (ABMT) without graft-
versus-host disease to improve survival and cure in leukemia. The present
study shows that bone marrow transplantation (BMT) using syngeneic bone
marrow activated with interleukin-2 (ABM) for 24 hours in vitro, followed
by interleukin-2 (IL-2) therapy, was superior to BMT with fresh, syngeneic
bone marrow (FBM) in terms of survival and cure in mice with acute myeloid
leukemia (P less than .001) and led to normal hematopoietic reconstitution.
Addition of IL-2 therapy after BMT with FBM did not improve the results
over BMT with FBM alone (P = .98). These results suggest that the GVL
effect of ABMT can be enhanced by using ABM for BMT followed by IL-2
therapy without compromising engraftment.
Volume 76,
Issue 11,
pp. 2187-2190,
12/01/1990
Copyright © 1990 by The American Society of Hematology
